ACNE
No
WATER RETENTION
No
HBR
No
HEPATOTOXICITY
No
AROMATIZATION
No
MANUFACTURER
Beligas
WAREHOUSE
International Warehouse 3
SUBSTANCE
GHRH Peptide
Introducing Tesamorelin: a cutting-edge growth hormone-releasing factor (GRF) designed to effectively target excess abdominal fat linked to specific HIV treatments, known as lipodystrophy (LYE-poe-DIS-troe-fee). While Tesamorelin is a powerful tool for managing this condition, it is essential to note that it is not intended for weight loss or obesity treatment.
Approved for use in HIV-positive patients experiencing lipodystrophy, Tesamorelin focuses on reducing stubborn abdominal fat, offering hope and support for those affected.
Use Limitations:
As research on the long-term cardiovascular safety and benefits of Tesamorelin remains limited, it?s vital to regularly evaluate treatment effectiveness. This includes monitoring visceral fat reduction through waist circumference or CT scans. Keep in mind that Tesamorelin does not aid in weight management and has no proven impact on the adherence to antiretroviral therapies for individuals with HIV.
General Dosing Guidelines:
The recommended dosage of Tesamorelin is 2 mg, administered subcutaneously once daily, preferably in the abdomen. Be sure to rotate injection sites, avoiding areas with scar tissue, bruising, or near the navel for optimal results.
Reconstitution Instructions:
Tesamorelin requires reconstitution with the provided diluent. To properly mix, gently roll a 2 mg vial with 2.1 mL of diluent in your hands for approximately 30 seconds?avoid vigorous shaking. Detailed reconstitution guidance can be found in the INSTRUCTIONS FOR USE leaflet included with the product. Administer Tesamorelin immediately after reconstitution and discard any unused solution. Remember, the reconstituted solution should not be frozen or refrigerated.
Administration:
Before injecting, visually inspect the reconstituted Tesamorelin solution for clarity and color. Only proceed with the injection if the solution appears clear, colorless, and free from particles. The injection should be made subcutaneously into the abdominal skin, rotating sites to ensure comfort and efficacy. Avoid areas with scar tissue, bruises, or the navel.